Characterization of a Novel Monoclonal Antibody for Serine-129 Phosphorylated α-Synuclein: A Potential Application for Clinical and Basic Research

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Mar 7

PMID 35250825

Authors

Weijin Liu

Qidi Zhang

Hao Xing

Ge Gao

Jia Liu

Yue Huang

Hui Yang

Affiliations

Soon will be listed here.

Abstract

The Lewy bodies (LBs) are the pathological hallmark of Parkinson's disease (PD). More than 90% of α-synuclein (α-syn) within LBs is phosphorylated at the serine-129 residue [pSer129 α-syn (p-α-syn)]. Although various studies have revealed that this abnormally elevated p-α-syn acts as a pathological biomarker and is involved in the pathogenic process of PD, the exact pathophysiological mechanisms of p-α-syn are still not fully understood. Therefore, the development of specific and reliable tools for p-α-syn detection is important. In this study, we generated a novel p-α-syn mouse monoclonal antibody (C140S) using hybridoma technology. To further identify the characteristics of C140S, we performed several assays using recombinant proteins, along with assays utilizing the brains of Thy1-SNCA transgenic (Tg) mice, the preformed fibril (PFF)-treated neurons, and the brain sections of patients with PD. Our C140S specifically recognized human and mouse p-α-syn proteins both and , and similar to commercial p-α-syn antibodies, the C140S detected higher levels of p-α-syn in the midbrain of the Tg mice. Using immunogold electron microscopy, these p-α-syn particles were partly deposited in the cytoplasm and colocalized with the outer mitochondrial membrane. In addition, the C140S recognized p-α-syn pathologies in the PFF-treated neurons and the amygdala of patients with PD. Overall, the C140S antibody was a specific and potential research tool in the detection and mechanistic studies of pathogenic p-α-syn in PD and related synucleinopathies.

Citing Articles

Bridging the gap: investigating the role of phosphorylation at the serine 129 site of α-synuclein in VAPB-PTPIP51 interactions.

Liu W, Lu Y, Liu J, Yu Y, Yang H Acta Neuropathol Commun. 2025; 13(1):40.

PMID: 39994794 PMC: 11849190. DOI: 10.1186/s40478-025-01949-6.

4-Oxo-2-Nonenal- and Agitation-Induced Aggregates of α-Synuclein and Phosphorylated α-Synuclein with Distinct Biophysical Properties and Biomedical Applications.

Wang T, Liu W, Zhang Q, Jiao J, Wang Z, Gao G Cells. 2024; 13(9.

PMID: 38727274 PMC: 11082957. DOI: 10.3390/cells13090739.

Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson's Disease.

Rademacher D Biomedicines. 2023; 11(4).

PMID: 37189807 PMC: 10136086. DOI: 10.3390/biomedicines11041187.

α-Synuclein decoy peptide protects mice against α-synuclein-induced memory loss.

Guo Q, Kawahata I, Jia W, Wang H, Cheng A, Yabuki Y CNS Neurosci Ther. 2023; 29(6):1547-1560.

PMID: 36786129 PMC: 10173724. DOI: 10.1111/cns.14120.

References

Luk K, Kehm V, Carroll J, Zhang B, OBrien P, Trojanowski J . Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012; 338(6109):949-53. PMC: 3552321. DOI: 10.1126/science.1227157. View

Pediaditakis I, Kodella K, Manatakis D, Le C, Hinojosa C, Tien-Street W . Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nat Commun. 2021; 12(1):5907. PMC: 8501050. DOI: 10.1038/s41467-021-26066-5. View

Shaltouki A, Hsieh C, Kim M, Wang X . Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models. Acta Neuropathol. 2018; 136(4):607-620. PMC: 6123262. DOI: 10.1007/s00401-018-1873-4. View

Braak H, Del Tredici K, Rub U, de Vos R, Jansen Steur E, Braak E . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2002; 24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. View

Volpicelli-Daley L, Luk K, Lee V . Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc. 2014; 9(9):2135-46. PMC: 4372899. DOI: 10.1038/nprot.2014.143. View

Delic V, Chandra S, Abdelmotilib H, Maltbie T, Wang S, Kem D . Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies. J Comp Neurol. 2018; 526(12):1978-1990. PMC: 6031478. DOI: 10.1002/cne.24468. View

Goedert M, Spillantini M, Del Tredici K, Braak H . 100 years of Lewy pathology. Nat Rev Neurol. 2012; 9(1):13-24. DOI: 10.1038/nrneurol.2012.242. View

Pinho R, Paiva I, Jercic K, Fonseca-Ornelas L, Gerhardt E, Fahlbusch C . Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein. Hum Mol Genet. 2018; 28(1):31-50. DOI: 10.1093/hmg/ddy326. View

Mbefo M, Paleologou K, Boucharaba A, Oueslati A, Schell H, Fournier M . Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem. 2009; 285(4):2807-22. PMC: 2807335. DOI: 10.1074/jbc.M109.081950. View

10.

Anderson J, Walker D, Goldstein J, de Laat R, Banducci K, Caccavello R . Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem. 2006; 281(40):29739-52. DOI: 10.1074/jbc.M600933200. View

11.

Fares M, Jagannath S, Lashuel H . Reverse engineering Lewy bodies: how far have we come and how far can we go?. Nat Rev Neurosci. 2021; 22(2):111-131. DOI: 10.1038/s41583-020-00416-6. View

12.

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

13.

Mahul-Mellier A, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F . The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020; 117(9):4971-4982. PMC: 7060668. DOI: 10.1073/pnas.1913904117. View

14.

Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U . Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol. 2003; 249 Suppl 3:III/1-5. DOI: 10.1007/s00415-002-1301-4. View

15.

Hansson O . Biomarkers for neurodegenerative diseases. Nat Med. 2021; 27(6):954-963. DOI: 10.1038/s41591-021-01382-x. View

16.

Mao X, Ou M, Karuppagounder S, Kam T, Yin X, Xiong Y . Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science. 2016; 353(6307). PMC: 5510615. DOI: 10.1126/science.aah3374. View

17.

Tian H, Lu Y, Liu J, Liu W, Lu L, Duan C . Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein. Front Aging Neurosci. 2018; 10:173. PMC: 6008559. DOI: 10.3389/fnagi.2018.00173. View

18.

Trier N, Hansen P, Houen G . Production and characterization of peptide antibodies. Methods. 2011; 56(2):136-44. DOI: 10.1016/j.ymeth.2011.12.001. View

19.

Colom-Cadena M, Pegueroles J, Herrmann A, Henstridge C, Munoz L, Querol-Vilaseca M . Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Brain. 2017; 140(12):3204-3214. PMC: 5841145. DOI: 10.1093/brain/awx275. View

20.

Chen L, Feany M . Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005; 8(5):657-63. DOI: 10.1038/nn1443. View